Location History:
- Seongnam-Si, KR (2007)
- Yongin-si, KR (2014)
- Gyeonggi-do, KR (2017 - 2018)
Company Filing History:
Years Active: 2007-2018
Title: Innovator Dong-Hee Lee: Pioneering Arthritis Treatment
Introduction
Dong-Hee Lee, an accomplished inventor from Gyeonggi-do, South Korea, has made significant contributions to the field of pharmaceuticals. With a total of two patents to his name, he is dedicated to advancing medical treatments, particularly in the area of arthritis.
Latest Patents
One of Lee's latest innovations is a patented method for treating arthritis using an IK factor or a nucleic acid encoding IK factor. This pharmaceutical composition includes a gene delivery vehicle that integrates the IK factor or its fragment, providing a novel approach to treating and preventing arthritis. The active ingredients in this composition, derived from living organisms, exhibit minimal side effects when administered over extended periods. This characteristic ensures safety for patients while effectively targeting the upstream mechanisms associated with arthritis suppression.
Career Highlights
Throughout his career, Dong-Hee Lee has collaborated with notable organizations, including the Catholic University Industry Academic Cooperation Foundation and Cellinbio Co., Ltd. His work in these institutions has contributed to his research and development endeavors, further enhancing his expertise in innovative healthcare solutions.
Collaborations
In his journey as an inventor, Lee has worked alongside distinguished coworkers, including Jae-Hwan Nam and Hye-Lim Park. These collaborative efforts have allowed for a multidisciplinary approach to solving complex medical challenges and driving innovation in the pharmaceutical field.
Conclusion
Dong-Hee Lee's contributions to arthritis treatment and pharmaceuticals demonstrate his commitment to advancing medical science. With promising patents and collaborative work, he continues to play a vital role in the ongoing innovation landscape, aspiring to improve the quality of life for those affected by arthritis.